NBTX
Nanobiotix S.A.
$43.55
-0.30%
2026-08-21
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Key Fundamentals
Forward P/E
-113.05
EPS (TTM)
$-0.57
Revenue Growth (YoY)
186.8%
Profit Margin
-73.5%
Beta
0.57
Market Cap
$1.95B
Avg Volume (10D)
135K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$45.74
60D Low
$31.68
Avg Volume
113K
Latest Close
$43.55
Get breakout alerts for NBTX
Sign up for Breakout Scanner to receive daily notifications when NBTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Nanobiotix S.A. (NBTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NBTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NBTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.